Brokers Issue Forecasts for AKRO FY2025 Earnings

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Akero Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($4.70) per share for the year. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.96) per share.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15).

Other analysts have also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Thursday, January 16th. Citigroup began coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 price objective on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.83.

Akero Therapeutics Trading Up 1.8 %

NASDAQ AKRO opened at $25.60 on Wednesday. The stock has a market cap of $1.79 billion, a P/E ratio of -6.83 and a beta of -0.19. Akero Therapeutics has a fifty-two week low of $15.32 and a fifty-two week high of $37.00. The stock has a 50 day simple moving average of $28.83 and a two-hundred day simple moving average of $28.06. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25.

Insiders Place Their Bets

In related news, COO Jonathan Young sold 10,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $28.03, for a total value of $280,300.00. Following the transaction, the chief operating officer now directly owns 218,083 shares of the company’s stock, valued at approximately $6,112,866.49. This trade represents a 4.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Catriona Yale sold 15,485 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $32.62, for a total value of $505,120.70. Following the completion of the sale, the insider now owns 74,158 shares of the company’s stock, valued at approximately $2,419,033.96. The trade was a 17.27 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 262,135 shares of company stock valued at $8,223,000. Company insiders own 7.94% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AKRO. Mirae Asset Global Investments Co. Ltd. lifted its stake in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after purchasing an additional 446 shares in the last quarter. Eastern Bank purchased a new stake in shares of Akero Therapeutics in the third quarter worth about $100,000. Summit Financial Wealth Advisors LLC bought a new position in Akero Therapeutics during the third quarter valued at approximately $205,000. Victory Capital Management Inc. bought a new position in shares of Akero Therapeutics during the 3rd quarter valued at approximately $211,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Akero Therapeutics in the third quarter worth $265,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.